NRAS and melanoma: To investigate the potential involvement of autophagy in modulating the response to encorafenib, Li et al. [53] studied encorafenib in four human melanoma cell lines harboring the BRAFV600E mutation, A375, G361, RPMI7951 and SK-MEL-24 cells, while using C8161, a human melanoma cell line carrying wild-type BRAF/NRAS, as a control.